Follistatin 344 Side Effects: What the Evidence Shows (2026)
Follistatin 344 has limited human safety data, which makes characterizing its side effects more difficult than for peptides with full clinical trial records. What is known comes from animal studies, preclinical research, and a small number of reports from clinical use. Here is an honest summary.
Known and Reported Side Effects
Commonly reported in clinical use:
- Injection site reactions (redness, swelling, minor pain) — most common
- Temporary fatigue or lethargy, particularly in the first 1–2 weeks
- Mild headache
- Transient changes in appetite
Reported less frequently:
- Elevated creatine kinase levels (marker of muscle breakdown or stress) — monitor with labs
- Joint discomfort in some users, possibly related to rapid muscle tissue changes
- Sleep disturbances, typically in the first weeks
Theoretical risks based on mechanism:
- Tumor promotion concern: Follistatin is an activin antagonist and suppresses myostatin. Because it reduces negative regulation of cell growth, there is a theoretical concern that it could accelerate pre-existing tumor growth by removing normal growth restraints. Human data on this is essentially absent; it is a precautionary concern based on mechanism
- Ovarian hyperstimulation: In animal models, follistatin disrupts reproductive axis regulation. Women should exercise particular caution and discuss hormonal implications with a provider before use
Side Effects by Evidence Quality
| Side Effect | Evidence Source | Confidence |
|---|---|---|
| Injection site reactions | Clinical use reports | High |
| Fatigue (early weeks) | Clinical use reports | Moderate |
| Elevated CK levels | Lab monitoring | Moderate |
| Tumor growth promotion | Animal/mechanistic | Low (theoretical) |
| Reproductive disruption | Animal studies | Low-Moderate |
| Liver enzyme elevation | Preclinical | Low |
Follistatin 344 vs. Follistatin 315: Are the Side Effects Different?
Follistatin 344 and Follistatin 315 are isoforms of the same protein, differing in how they bind to heparan sulfate proteoglycans. Follistatin 344 has stronger tissue localization; Follistatin 315 circulates more systemically.
Practical implication: Follistatin 315 is sometimes considered to have a broader systemic effect (including potential ovarian effects), while Follistatin 344 may be more localized to the injection site and surrounding tissue. However, human data differentiating their side effect profiles is essentially non-existent. Treat both with similar caution.
Who Should Not Use Follistatin 344
Follistatin 344 should be avoided or approached with extreme caution in:
- Anyone with a personal or family history of cancer — the theoretical tumor promotion risk is not worth taking without extensive oncology consultation
- Women who are or may be pregnant — follistatin plays a role in reproductive biology and embryonic development; use during pregnancy is contraindicated
- Women with known or suspected reproductive disorders — polycystic ovary syndrome (PCOS), endometriosis, or fertility concerns should be discussed with a physician before any follistatin use
- Individuals with elevated liver enzymes — until liver function is established as normal
- Anyone without physician supervision — given the limited human safety data and theoretical risks, self-administration without medical oversight is inadvisable
What Are FLGR 242 Peptide Side Effects?
Some users searching for follistatin-related side effects use the term "FLGR 242." This likely refers to a specific formulation or product description containing follistatin or a follistatin-related fragment. The side effect profile overlaps substantially with what is described above for Follistatin 344.
If you encountered "FLGR 242" as a product designation, verify the exact compound with your provider — side effects will depend on the specific peptide sequence and dosing.
